Literature DB >> 21224839

Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN.

Dan Turner1, Simon P L Travis, Anne M Griffiths, Frank M Ruemmele, Arie Levine, Eric I Benchimol, Marla Dubinsky, George Alex, Robert N Baldassano, Jacob C Langer, Robert Shamberger, Jeffrey S Hyams, Salvatore Cucchiara, Athos Bousvaros, Johanna C Escher, James Markowitz, David C Wilson, Gert van Assche, Richard K Russell.   

Abstract

OBJECTIVES: Acute severe ulcerative colitis (ASC) is a potentially life-threatening disease. We aimed to formulate guidelines for managing ASC in children based on systematic review of the literature and robust consensus process. This manuscript is a product of a joint effort of the ECCO (European Crohn's and Colitis Organization), the Pediatric Porto Inflammatory Bowel Disease (IBD) Working group of ESPGHAN (European Society of Pediatric Gastroenterology, Hepatology, and Nutrition) and ESPGHAN.
METHODS: A group of 19 experts in pediatric IBD participated in an iterative consensus process including two face-to-face meetings. A total of 17 predefined questions were addressed by working subgroups based on a systematic review of the literature.
RESULTS: The recommendations and practice points were eventually endorsed with a consensus rate of at least 95% regarding: definitions, initial evaluation, standard therapy, timing of second-line therapy, the role of endoscopic evaluation and heparin prophylaxis, how to administer second-line medical therapy, how to assess response, surgical considerations, and discharge recommendations. A management flowchart is presented based on daily scoring of the Pediatric Ulcerative Colitis Activity Index (PUCAI), along with 28 formal recommendations and 34 practice points.
CONCLUSIONS: These guidelines provide clinically useful points to guide the management of ASC in children. Taken together, the recommendations offer a standardized protocol that allows effective monitoring of disease progress and timely treatment escalation when needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21224839     DOI: 10.1038/ajg.2010.481

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

Review 1.  Contemporary Medical Management of Acute Severe Ulcerative Colitis.

Authors:  Kaitlin G Whaley; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2019-01-01       Impact factor: 5.325

Review 2.  Role of surgery in pediatric ulcerative colitis.

Authors:  Emanuela Ceriati; Francesco De Peppo; Massimo Rivosecchi
Journal:  Pediatr Surg Int       Date:  2013-10-31       Impact factor: 1.827

3.  Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences.

Authors:  Hiroshi Nakase; Hans Herfarth
Journal:  Inflamm Intest Dis       Date:  2016-01-23

Review 4.  Pediatric ulcerative colitis: a practical guide to management.

Authors:  Brian P Regan; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

Review 5.  Inflammatory Bowel Disease in Primary Immunodeficiencies.

Authors:  Judith R Kelsen; Kathleen E Sullivan
Journal:  Curr Allergy Asthma Rep       Date:  2017-08       Impact factor: 4.806

Review 6.  Medical and Surgical Management of Pediatric Ulcerative Colitis.

Authors:  José M Cabrera; Thomas T Sato
Journal:  Clin Colon Rectal Surg       Date:  2018-02-25

Review 7.  CMV Infection in Pediatric IBD.

Authors:  Anat Yerushalmy-Feler; Sharona Kern-Isaacs; Shlomi Cohen
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 8.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

Review 9.  History of and current issues affecting surgery for pediatric ulcerative colitis.

Authors:  Keiichi Uchida; Toshimitsu Araki; Masato Kusunoki
Journal:  Surg Today       Date:  2012-12-01       Impact factor: 2.549

Review 10.  Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease.

Authors:  Parambir S Dulai; Corey A Siegel; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.